Cargando…

Performance of EUS-FNA for mediastinal lymphadenopathy: impact on patient management and costs in low-volume EUS centers

BACKGROUND: Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) of mediastinal lymphadenopathy has been shown to be a valuable diagnostic tool in high-volume EUS centers (≥50 mediastinal EUS-FNA/endoscopist/year). Our goal was to assess the diagnostic accuracy of EUS-FNA and its impact on...

Descripción completa

Detalles Bibliográficos
Autores principales: Hirdes, Meike M. C., Schwartz, Matthijs P., Tytgat, Kristien M. A. J., Schlösser, Noёl J., Sie-Go, Daisy M. D. S., Brink, Menno A., Oldenburg, Bas, Siersema, Peter D., Vleggaar, Frank P.
Formato: Texto
Lenguaje:English
Publicado: Springer-Verlag 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2939341/
https://www.ncbi.nlm.nih.gov/pubmed/20177920
http://dx.doi.org/10.1007/s00464-010-0946-9
_version_ 1782186708523024384
author Hirdes, Meike M. C.
Schwartz, Matthijs P.
Tytgat, Kristien M. A. J.
Schlösser, Noёl J.
Sie-Go, Daisy M. D. S.
Brink, Menno A.
Oldenburg, Bas
Siersema, Peter D.
Vleggaar, Frank P.
author_facet Hirdes, Meike M. C.
Schwartz, Matthijs P.
Tytgat, Kristien M. A. J.
Schlösser, Noёl J.
Sie-Go, Daisy M. D. S.
Brink, Menno A.
Oldenburg, Bas
Siersema, Peter D.
Vleggaar, Frank P.
author_sort Hirdes, Meike M. C.
collection PubMed
description BACKGROUND: Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) of mediastinal lymphadenopathy has been shown to be a valuable diagnostic tool in high-volume EUS centers (≥50 mediastinal EUS-FNA/endoscopist/year). Our goal was to assess the diagnostic accuracy of EUS-FNA and its impact on clinical management and costs in low-volume EUS centers (<50 mediastinal EUS-FNA/endoscopist/year). METHODS: Consecutive patients referred to two Dutch endoscopy centers in the period 2002–2008 for EUS-FNA of mediastinal lymphadenopathy were reviewed. The gold standard for a cytological diagnosis was histological confirmation or clinical follow-up of more than 6 months with repeat imaging. The impact of EUS-FNA on clinical management was subdivided into a positive impact by providing (1) adequate cytology that influenced the decision to perform surgery or (2) a diagnosis of a benign inflammatory disorder, and a negative impact which was subdivided into (1) false-negative or inconclusive cytology or (2) an adequate cytological diagnosis that did not influence patient management. Costs of an alternative diagnostic work-up without EUS-FNA, as established by an expert panel, were compared to costs of the actual work-up. RESULTS: In total, 213 patients (71% male, median age = 61 years, range = 23–88 years) underwent EUS-FNA. Sensitivity, specificity, and negative and positive predictive values were 89%, 100%, 80%, and 100%, respectively. EUS-FNA had a positive impact on clinical management in 84% of cases by either influencing the decision to perform surgery (49%) or excluding malignant lymphadenopathy (35%), and a negative impact in 7% of cases because of inadequate (3%) or false-negative (4%) cytology. In 9% of cases, EUS-FNA was performed without an established indication. Two nonfatal perforations occurred (0.9%). Total cost reduction was €100,593, with a mean cost reduction of €472 (SD = €607) per patient. CONCLUSIONS: Mediastinal EUS-FNA can be performed in low-volume EUS centers without compromising diagnostic accuracy. Moreover, EUS-FNA plays an important role in the management of patients with mediastinal lymphadenopathy and reduces total diagnostic costs.
format Text
id pubmed-2939341
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Springer-Verlag
record_format MEDLINE/PubMed
spelling pubmed-29393412010-10-05 Performance of EUS-FNA for mediastinal lymphadenopathy: impact on patient management and costs in low-volume EUS centers Hirdes, Meike M. C. Schwartz, Matthijs P. Tytgat, Kristien M. A. J. Schlösser, Noёl J. Sie-Go, Daisy M. D. S. Brink, Menno A. Oldenburg, Bas Siersema, Peter D. Vleggaar, Frank P. Surg Endosc Article BACKGROUND: Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) of mediastinal lymphadenopathy has been shown to be a valuable diagnostic tool in high-volume EUS centers (≥50 mediastinal EUS-FNA/endoscopist/year). Our goal was to assess the diagnostic accuracy of EUS-FNA and its impact on clinical management and costs in low-volume EUS centers (<50 mediastinal EUS-FNA/endoscopist/year). METHODS: Consecutive patients referred to two Dutch endoscopy centers in the period 2002–2008 for EUS-FNA of mediastinal lymphadenopathy were reviewed. The gold standard for a cytological diagnosis was histological confirmation or clinical follow-up of more than 6 months with repeat imaging. The impact of EUS-FNA on clinical management was subdivided into a positive impact by providing (1) adequate cytology that influenced the decision to perform surgery or (2) a diagnosis of a benign inflammatory disorder, and a negative impact which was subdivided into (1) false-negative or inconclusive cytology or (2) an adequate cytological diagnosis that did not influence patient management. Costs of an alternative diagnostic work-up without EUS-FNA, as established by an expert panel, were compared to costs of the actual work-up. RESULTS: In total, 213 patients (71% male, median age = 61 years, range = 23–88 years) underwent EUS-FNA. Sensitivity, specificity, and negative and positive predictive values were 89%, 100%, 80%, and 100%, respectively. EUS-FNA had a positive impact on clinical management in 84% of cases by either influencing the decision to perform surgery (49%) or excluding malignant lymphadenopathy (35%), and a negative impact in 7% of cases because of inadequate (3%) or false-negative (4%) cytology. In 9% of cases, EUS-FNA was performed without an established indication. Two nonfatal perforations occurred (0.9%). Total cost reduction was €100,593, with a mean cost reduction of €472 (SD = €607) per patient. CONCLUSIONS: Mediastinal EUS-FNA can be performed in low-volume EUS centers without compromising diagnostic accuracy. Moreover, EUS-FNA plays an important role in the management of patients with mediastinal lymphadenopathy and reduces total diagnostic costs. Springer-Verlag 2010-02-23 2010 /pmc/articles/PMC2939341/ /pubmed/20177920 http://dx.doi.org/10.1007/s00464-010-0946-9 Text en © The Author(s) 2010 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
spellingShingle Article
Hirdes, Meike M. C.
Schwartz, Matthijs P.
Tytgat, Kristien M. A. J.
Schlösser, Noёl J.
Sie-Go, Daisy M. D. S.
Brink, Menno A.
Oldenburg, Bas
Siersema, Peter D.
Vleggaar, Frank P.
Performance of EUS-FNA for mediastinal lymphadenopathy: impact on patient management and costs in low-volume EUS centers
title Performance of EUS-FNA for mediastinal lymphadenopathy: impact on patient management and costs in low-volume EUS centers
title_full Performance of EUS-FNA for mediastinal lymphadenopathy: impact on patient management and costs in low-volume EUS centers
title_fullStr Performance of EUS-FNA for mediastinal lymphadenopathy: impact on patient management and costs in low-volume EUS centers
title_full_unstemmed Performance of EUS-FNA for mediastinal lymphadenopathy: impact on patient management and costs in low-volume EUS centers
title_short Performance of EUS-FNA for mediastinal lymphadenopathy: impact on patient management and costs in low-volume EUS centers
title_sort performance of eus-fna for mediastinal lymphadenopathy: impact on patient management and costs in low-volume eus centers
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2939341/
https://www.ncbi.nlm.nih.gov/pubmed/20177920
http://dx.doi.org/10.1007/s00464-010-0946-9
work_keys_str_mv AT hirdesmeikemc performanceofeusfnaformediastinallymphadenopathyimpactonpatientmanagementandcostsinlowvolumeeuscenters
AT schwartzmatthijsp performanceofeusfnaformediastinallymphadenopathyimpactonpatientmanagementandcostsinlowvolumeeuscenters
AT tytgatkristienmaj performanceofeusfnaformediastinallymphadenopathyimpactonpatientmanagementandcostsinlowvolumeeuscenters
AT schlossernoëlj performanceofeusfnaformediastinallymphadenopathyimpactonpatientmanagementandcostsinlowvolumeeuscenters
AT siegodaisymds performanceofeusfnaformediastinallymphadenopathyimpactonpatientmanagementandcostsinlowvolumeeuscenters
AT brinkmennoa performanceofeusfnaformediastinallymphadenopathyimpactonpatientmanagementandcostsinlowvolumeeuscenters
AT oldenburgbas performanceofeusfnaformediastinallymphadenopathyimpactonpatientmanagementandcostsinlowvolumeeuscenters
AT siersemapeterd performanceofeusfnaformediastinallymphadenopathyimpactonpatientmanagementandcostsinlowvolumeeuscenters
AT vleggaarfrankp performanceofeusfnaformediastinallymphadenopathyimpactonpatientmanagementandcostsinlowvolumeeuscenters